US 10,105,399 B2Granted

Methods and compositions for treatment of bone defects with placental cell populations

AssigneeCelularity Inc.

InventorsJames W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.

Claims20

Dependent claims

A method for treating a bone defect in a subject, wherein said bone defect is an osteolytic lesion associated with multiple myeloma, bone cancer, or metastatic cancer characterized by bone metastases, comprising administering to a subject in need thereof an implantable or injectable composition comprising a population of placental stem cells,

wherein said population is predominantly CD34−, CD10+, CD105+, and CD200+;
wherein said stem cells express genes at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs);
and wherein said genes comprise CPA4, TCF21, VTN, B4GALT6, FLJ10781, or NUAK1;
thereby treating the bone defect in the subject.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 15/093,185Filed 7 Apr 2016 · division
Priority: 23 Oct 2006
Published: US 2017/0056452 A12 Mar 2017
Granted: 23 Oct 2018
Term ends: Not estimatedThe source records don’t support an estimate.

Classification24 codes

A61K 35/50
Reproductive organs: placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 47/36
Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates: polysaccharides; Derivatives thereof, e.g. gums, starch, alginate,…
A61K 47/42
Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates: proteins; Polypeptides; Degradation products thereof; Derivatives…

Family

Application60/853,971Us provisional application · filed 23 Oct 2006
Application60/855,629Us provisional application · filed 30 Oct 2006
Application60/997,022Us provisional application · filed 28 Sep 2007
Application11/877,475Parent of this division · filed 23 Oct 2007
Application14/028,228Parent of this division · filed 16 Sep 2013
US 8,562,972 B2Parent of this division · filed 22 Oct 2013
US 2017/0056452 A1Pre-grant publication · published 2 Mar 2017
US 9,339,520 B2Parent of this division
US 2008/0213228 A1Published application
US 2014/0017211 A1Published application
US 10,105,399 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key